Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis

被引：0
作者：
Maëlle Chappuis
Chloé Rousseau
Emma Bajeux
Sandrine Wiertlewski
David Laplaud
Emmanuelle Le Page
Laure Michel
Gilles Edan
Anne Kerbrat
机构：
[1] University Hospital,Department of Neurology
[2] University Hospital,Research Management Department
[3] University Hospital,Department of Epidemiology and Public Health
[4] University Hospital,Department of Neurology
[5] University Hospital,CIC
来源：
Journal of Neurology | 2023年 / 270卷
关键词：
Multiple sclerosis; Treatment discontinuation; Age;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：413 / 422
页数：9
相关论文
共 50 条
  • [1] Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis
    Chappuis, Maelle
    Rousseau, Chloe
    Bajeux, Emma
    Wiertlewski, Sandrine
    Laplaud, David
    Le Page, Emmanuelle
    Michel, Laure
    Edan, Gilles
    Kerbrat, Anne
    JOURNAL OF NEUROLOGY, 2023, 270 (01) : 413 - 422
  • [2] Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity
    Anne-Laure Kaminsky
    Abdou Yacoubou Omorou
    Marc Soudant
    Sophie Pittion-Vouyovitch
    Maud Michaud
    René Anxionnat
    Francis Guillemin
    Marc Debouverie
    Guillaume Mathey
    Journal of Neurology, 2020, 267 : 3518 - 3527
  • [3] Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity
    Kaminsky, Anne-Laure
    Omorou, Abdou Yacoubou
    Soudant, Marc
    Pittion-Vouyovitch, Sophie
    Michaud, Maud
    Anxionnat, Rene
    Guillemin, Francis
    Debouverie, Marc
    Mathey, Guillaume
    JOURNAL OF NEUROLOGY, 2020, 267 (12) : 3518 - 3527
  • [4] Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab
    Fagius, Jan
    Feresiadou, Amalia
    Larsson, Elna-Marie
    Burman, Joachim
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 12 : 82 - 87
  • [5] First-line disease-modifying therapies in paediatric multiple sclerosis: A comprehensive overview
    Jessica Johnston
    Tsz-Yin So
    Drugs, 2012, 72 (9) : 1195 - 1211
  • [6] Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
    James Bowen
    Rina Mehta
    Corey Pelletier
    Marc Tian
    Virginia Noxon
    Barbara H. Johnson
    Machaon Bonafede
    Advances in Therapy, 2020, 37 : 3163 - 3177
  • [7] Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
    Bowen, James
    Mehta, Rina
    Pelletier, Corey
    Tian, Marc
    Noxon, Virginia
    Johnson, Barbara H.
    Bonafede, Machaon
    ADVANCES IN THERAPY, 2020, 37 (07) : 3163 - 3177
  • [8] Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis
    Das, J.
    Snowden, J. A.
    Burman, J.
    Freedman, M. S.
    Atkins, H.
    Bowman, M.
    Burt, R. K.
    Saccardi, R.
    Innocenti, C.
    Mistry, S.
    Laud, P. J.
    Jessop, H.
    Sharrack, B.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (08) : 1198 - 1204
  • [9] Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs
    Degli Esposti, Luca
    Piccinni, Carlo
    Sangiorgi, Diego
    Perrone, Valentina
    Aledda, Lucia
    Marrosu, Maria Giovanna
    Lombardo, Fabio
    NEUROLOGICAL SCIENCES, 2017, 38 (04) : 589 - 594
  • [10] Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs
    Luca Degli Esposti
    Carlo Piccinni
    Diego Sangiorgi
    Valentina Perrone
    Lucia Aledda
    Maria Giovanna Marrosu
    Fabio Lombardo
    Neurological Sciences, 2017, 38 : 589 - 594
12345